Effect of DRB on the biological characteristics of human laryngeal carcinoma Hep-2 cell line.
In order to study the effect of 5, 6-Dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB) on the biological characteristics of human laryngeal carcinoma Hep-2 cell line in vitro, Hep-2 cells cultured in vitro were treated with different concentrations of DRB. Changes in cell proliferation, apoptotic rate and invasiveness were detected by MTT assay, flow cytometry (FCM) and matrigel in vitro invasion assay, respectively. It was found that DRB inhibited the proliferation of Hep-2 cells in a dose-and time-dependent manner. After being treated with 0, 10, 20, 40, 80 microm mol/L DRB for 24 h, the apoptotic rate in Hep-2 cells was (0.68+/-0.19)%, (1.95+/-0.12)%, (8.51+/-0.26)%, (11.26+/-0.17)% and (14.99+/-0.32)%, respectively. The matrigel in vitro invasion assay revealed that DRB began to inhibit the invasion of Hep-2 cells at the concentration of 5 microm mol/L, and with the increase of DRB concentration, the inhibitory effect was enhanced. It was suggested that DRB could influence the essential biological characteristics of Hep-2 cells, inhibit Hep-2 cells proliferation, reduce invasive ability and induce apoptosis of Hep-2 cells.
Wang
Jianting
J
Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. tingjianwang@yahoo.com.cn
Gong
Shusheng
S
Fu
Yong
Y
Xue
Qiuhong
Q
Chen
Guangli
G
Liu
Yingpeng
Y
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D003094:Collagen / Q000187:drug effects; D004004:Dichlororibofuranosylbenzimidazole / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005434:Flow Cytometry; D006801:Humans; D007202:Indicators and Reagents / Q000378:metabolism; D007797:Laminin / Q000187:drug effects; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D009361:Neoplasm Invasiveness / Q000503:physiopathology / Q000517:prevention & control; D011509:Proteoglycans / Q000187:drug effects; D013778:Tetrazolium Salts / Q000378:metabolism; D013997:Time Factors
D000970:Antineoplastic Agents; D004338:Drug Combinations; D007202:Indicators and Reagents; D007797:Laminin; D011509:Proteoglycans; D013778:Tetrazolium Salts; C059485:matrigel; D004004:Dichlororibofuranosylbenzimidazole; D003094:Collagen